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Several coronavirus disease 2019 (COVID-19) vaccines are 
currently in human trials. In June 2020, we surveyed 13,426 
people in 19 countries to determine potential acceptance 
rates and factors influencing acceptance of a COVID-19 vac-
cine. Of these, 71.5% of participants reported that they would 
be very or somewhat likely to take a COVID-19 vaccine, and 
61.4% reported that they would accept their employer’s rec-
ommendation to do so. Differences in acceptance rates ranged 
from almost 90% (in China) to less than 55% (in Russia). 
Respondents reporting higher levels of trust in information 
from government sources were more likely to accept a vaccine 
and take their employer’s advice to do so.
The COVID-19 pandemic is expected to continue to impose 
enormous burdens of morbidity and mortality while severely dis-
rupting societies and economies worldwide. Governments must be 
ready to ensure large-scale, equitable access and distribution of a 
COVID-19 vaccine if and when a safe and effective one becomes 
available. This will require sufficient health system capacity, as well 
as strategies to enhance trust in and acceptance of the vaccine and 
those who deliver it.
In 2015, the World Health Organization (WHO) Strategic 
Advisory Group of Experts on Immunization defined vaccine hesi-
tancy as a ’delay in acceptance or refusal of vaccination despite avail-
ability of vaccination services’1, which can vary in form and intensity 
based on when and where it occurs and what vaccine is involved, 
as has been confirmed in multiple studies2,3. Concern about vac-
cine hesitancy is growing worldwide4; in fact, WHO identified it as 
one of the top ten global health threats in 2019 (https://www.who.
int/news-room/spotlight/ten-threats-to-global-health-in-2019). 
In many countries, vaccine hesitancy and misinformation pres-
ent substantial obstacles to achieving coverage and community 
immunity5,6.
Governments, public health officials and advocacy groups 
must be prepared to address hesitancy and build vaccine literacy 
so that the public will accept immunization when appropriate. 
Anti-vaccination activists are already campaigning in multiple 
countries against the need for a vaccine, with some denying the 
existence of COVID-19 altogether7. Misinformation spread through 
multiple channels could have a considerable effect on the acceptance 
of a COVID-19 vaccine8. The accelerated pace of vaccine develop-
ment has further heightened public anxieties and could compro-
mise acceptance9.
Governments and societies must gauge current levels of will-
ingness to receive a potentially safe and effective COVID-19 vac-
cine and identify correlates of vaccine hesitancy and/or acceptance. 
We present findings from a survey of the likelihood of vaccine 
acceptance from a sample of 13,426 respondents in 19 countries.
Results
Survey respondents represented a random sample of the popula-
tions of 19 countries that comprise around 55% of the global popu-
lation. Their characteristics and a summary of their responses to 
the survey questions are listed in Table 1. Women were 53.5% of the 
study population, and 63.3% of all participants earned more than 
$32 per day. More than a third of the respondents (36.3%) had a 
university degree, and 62.4% were between 25 and 54 years old.
Respondents from China gave the highest proportion of positive 
responses (631 of 712 respondants, 88.6%) and the lowest propor-
tion of negative responses (5 of 712, 0.7%) when asked if they would 
take a ‘proven, safe and effective vaccine’. Respondents from Poland 
reported the highest proportion of negative responses (182 of 666, 
27.3%), whereas Russian respondents gave the lowest proportion of 
positive responses (373 of 680, 54.9%). The proportion of positive 
responses for all countries can be found in Extended Data Fig. 1.
When asked whether “You would accept a vaccine if it were rec-
ommended by your employer and was approved safe and effective 
by the government,” 31.9% (4,286 of 13,426) completely agreed, 
whereas 17.9% (2,411 of 13,426) somewhat or completely disagreed 
(Table 1). There was considerable variation by country, with China 
again having the highest proportion of positive responses (596 of 
712, 83.7%) and the lowest proportion of negative responses (26 of 
712, 3.7%). Russia had the highest proportion of negative responses 
(278 of 680, 40.9%) and the lowest proportion of respondents (184 
of 680, 27.1%) willing to accept their employer’s recommendation 
(Supplementary Table 1).
Table 2 summarizes results for the 16 regressions: one set of eight 
univariate regressions for the positive outcomes for the two ques-
tions of interest against the four demographic variables: whether 
or not the respondent or a family member was sick, cases per mil-
lion categorized as high/medium/low, mortality per million catego-
rized as high/medium/low and trust in government. People aged 
25–54, 55–64 and 65+ were more likely to accept the vaccine than 
those who were aged 18–24. This difference was strongest (odds 
ratio (OR) = 1.73; 95% confidence interval (CI) (1.48, 2.02)) when 
responses from the oldest age cohort and those from the young-
est age cohort were compared (Table 2). The opposite trend was 
observed in regard to acceptance of the vaccine if one’s employer 
required it. Gender differences were small, but the univariate 
association for both questions suggested that men were slightly 
less likely to respond positively than women, with an OR of 0.84 
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(95% CI (0.78, 0.91)) of men responding positively relative to 
women for the general question, and an OR of 0.87 (95% CI (0.81, 
0.93)) for the business-related question.
People earning more than $32 per day were 2.18 (95 CI% (1.79, 
2.64)) times more likely to respond positively to the general ques-
tion than people earning less than $2 per day. Higher levels of edu-
cation were also associated positively with vaccine acceptance on 
both questions. People who reported COVID-19 sickness in them-
selves or family members were no more likely to respond positively 
to the vaccine question than other respondents (OR = 0.97; 95% CI 
(0.87, 1.08)). Cases and mortality per million of a nation’s popula-
tion were associated with a higher likelihood of vaccine acceptance 
in countries with medium and high disease incidence and mortality.
Respondents who said that they trusted their government were 
more likely to accept a vaccine than those who said that they did not 
(OR = 1.67; 95% CI (1.54, 1.80)). Moreover, if an individual trusted 
their government, they were more likely to respond positively to 
their employer’s vaccine recommendation than someone who did 
not (OR = 2.34; 95% CI (2.20, 2.56)) (Table 2).
Discussion
We conducted a study of potential acceptance of a COVID-19 vac-
cine in 13,426 randomly selected individuals across 19 countries, 
most with a high COVID-19 burden. Of these, 71.5% responded 
that they would take a vaccine if it were proven safe and effective, 
and 61.4% said that they would get vaccinated if their employer rec-
ommended it (Table 1). However, we observed high heterogeneity 
in responses between countries. Furthermore, reporting one’s will-
ingness to get vaccinated might not be necessarily a good predic-
tor of acceptance, as vaccine decisions are multifactorial and can 
change over time.
The far-from-universal willingness to accept a COVID-19 vac-
cine is a cause for concern. Countries where acceptance exceeded 
80% tended to be Asian nations with strong trust in central govern-
ments (China, South Korea and Singapore). A relatively high ten-
dency toward acceptance in middle-income countries, such as Brazil, 
India and South Africa, was also observed. Unless and until the 
origins of such wide variation in willingness to accept a COVID-19 
vaccine is better understood and addressed, differences in vaccine 
coverage between countries could potentially delay global control 
of the pandemic and the ensuing societal and economic recovery.
Univariate variation among demographically defined groups 
was least among those with lower education and income levels. 
Future vaccine communication strategies should consider the 
level of health, scientific and general literacy in subpopulations, 
identify locally trusted sources of information10 and go beyond 
simply pronouncing that vaccines are safe and effective. Strategies 
to build vaccine literacy and acceptance should directly address 
community-specific concerns or misconceptions, address historic 
issues breeding distrust and be sensitive to religious or philosophi-
cal beliefs11. Researchers have identified promising interventions 
for building confidence and reducing vaccine hesitancy in different 
contexts12,13, but translating this evidence into large-scale vaccina-
tion campaigns will require particular awareness of and attention 
to existing public perceptions and felt needs. Engaging formal and 
informal opinion leaders within these communities will be key.
Additionally, we observed age-related associations with vaccine 
acceptance. Older people were more likely to report that they would 
take a vaccine, whereas younger respondents were more likely to 
accept an employer’s vaccine recommendation. This finding might 
reflect who was actually employed or employable at the time of the 
survey—an issue we did not investigate. Men in this study were less 
likely than women to accept vaccines in general or their employer’s 
recommendation to get vaccinated; however, this association was 
not strong. Those with a higher income were most likely to accept 
a vaccine than those with a lower income. These data could help 
governments, policymakers, health professionals and international 
organizations to more effectively target messaging around COVID-
19 vaccination programs.
The other source of concern was a discrepancy between reported 
acceptance of a COVID-19 vaccine and acceptance if vaccina-
tion was mandated by one’s employer. All respondents, regardless 
of nationality, reported that they would be less likely to accept a 
COVID-19 vaccine if it were mandated by employers. This find-
ing across all countries with both high and low reported vaccine 
acceptance proportions suggests that promoting voluntary accep-
tance is a better option for employers. It might seem easier to moni-
tor compliance among adults in the working age group if employers 
required it, but this could fail if it is perceived as limiting employees’ 
freedom of choice or a manifestation of employers’ self-interest14.
A careful balance is required between educating the public 
about the necessity for universal vaccine coverage and avoiding 
any suggestion of coercion. Respected community-based groups 
and non-governmental organizations, such as the Red Cross, which 
is considered to be impartial, are essential to help build trust in a 
future COVID-19 vaccine.
Table 1 | Description of participants and breakdown of the two 
COVID-19 vaccine questions
Overall
n 13,426
Gender (%)
 Female 7,172 (53.5)
 Male 6,129 (45.8)
 Other 94 (0.7)
Gapminder income level (%)
 <US$ 2 per day 447 (3.3)
 $2–$8 per day 840 (6.3)
 $8–$32 per day 3,011 (22.4)
 $32+ per day 8,498 (63.3)
 Did not answer 630 (4.7)
Education level (%)
 Less than high school 3,830 (28.6)
 High school or some college 4,692 (35.0)
 Bachelor’s degree 3,694 (27.6)
 Postgraduate degree 1,179 (8.8)
Age group in years (%)
 18–24 2,057 (15.4)
 25–54 8,360 (62.4)
 55–64 1,493 (11.1)
 65+ 1,485 (11.1)
Accept COVID-19 vaccine if generally available (%)
 Completely agree 6,288 (46.8)
 Somewhat agree 3,316 (24.7)
 Neutral/no opinion 1,912 (14.2)
 Somewhat disagree 819 (6.1)
 Completely disagree 1,091 (8.1)
Accept COVID-19 vaccine if employer recommended it (%)
 Completely agree 4,286 (31.9)
 Somewhat agree 3,957 (29.5)
 Neutral/no opinion 2,772 (20.6)
 Somewhat disagree 1,090 (8.1)
 Completely disagree 1,321 (9.8)
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Arguably, trust is an intrinsic and potentially modifiable compo-
nent of successful uptake of a COVID-19 vaccine. Our findings show 
that trust in government is strongly associated with vaccine accep-
tance and can contribute to public compliance with recommended 
actions15. Lessons learned from previous infectious disease out-
breaks and public health emergencies, including HIV, H1N1, SARS, 
MERS and Ebola, remind us that trusted sources of information and 
guidance are fundamental to disease control16. However, addressing 
vaccine hesitancy requires more than building trust. It is a multi-
factorial, complex and context-dependent endeavor that must be 
addressed simultaneously at global, national and sub-national levels.
Clear and consistent communication by government officials 
is crucial to building public confidence in vaccine progams. This 
includes explaining how vaccines work, as well as how they are devel-
oped, from recruitment to regulatory approval based on safety and 
efficacy. Effective campaigns should also aim to carefully explain a 
vaccine’s level of effectiveness, the time needed for protection (with 
multiple doses, if required) and the importance of population-wide 
coverage to achieve community immunity. Instilling public confi-
dence in regulatory agency reviews of vaccine safety and effective-
ness will be important. Credible and culturally informed health 
communication is vital in influencing positive health behaviors17,18, 
as has been observed with respect to encouraging people to cooper-
ate with COVID-19 control measures. This includes preparing the 
public and leaders of civic, religious and fraternal organizations that 
are respected within various sectors of society and local communi-
ties, as well as the private sector, for a mass vaccination program 
with credible spokespeople, local engagement, accurate information 
and technological support.
This study had limitations. It must be kept in mind that all pub-
lic surveys of the type reported here are snapshots taken at a point 
in time. This particular survey was conducted in the context of a 
highly dynamic and changing landscape, with daily variations in 
perceived disease threat and COVID-19 vaccine development itself.
In the 3 months since this survey was conducted, several highly 
visible events have affected COVID-19 vaccine development. A 
phase III trial of one of the most visible vaccine candidates was 
put on hold due to the report of a serious adverse event, although 
that hold was later lifted19. The Russian government, on the other 
hand, has made a vaccine available for general use on the basis of 
extremely limited data20. A group of former US Food and Drug 
Adminstration commissioners and several companies developing 
COVID-19 vaccines and biomedical advisory bodies have urged 
the US federal government to base any pending vaccine approv-
als on clinical data and not bend to political pressure from the 
incumbent US president to approve a vaccine before the US elec-
tions (https://www.washingtonpost.com/opinions/2020/09/29/
former-fda-commissioners-coronavirus-vaccine-trump/).
In the context of these developments that post-date our 
survey, subsequent national surveys in the United States and 
elsewhere have suggested strongly that public hesitancy to a 
COVID-19 vaccine is now greater than that which we report here 
( h t t p s :  / / w w w . k f  f .  o r g / c o r o n a v i r  u s - c o v i d - 1 9 / p r e s s - r e l e a s e / 
 p o l l - mo s t - a m e ri c a n s - w or r y -p o l it ic al -p re ss ur e- wi ll -l ea d- to - 
p re ma tu re -a pp ro va l - o f - a - c o v i d - 1 9 - v a c c i n e - h a l f - s a y - t h ey - w o u l d - 
n o t  -  g e  t  -a -  f  re  e-  va cc ine-approved-before-elect ion-day/) . 
T hi s can only intensify the vaccine communications challenges dis-
cussed above.
In most of the 19 countries surveyed in our study, current levels 
of willingness to accept a COVID-19 vaccine are insufficient to meet 
the requirements for community immunity. To build increased trust 
among the general population, the elements that define and build 
trust must be understood and interventions crafted accordingly. 
It is increasingly clear that transparent, evidence-informed policy 
and clear, accurate communication will be required of all relevant 
stakeholders. The ongoing pandemic provides the public health 
community with an important opportunity to build vaccine liter-
acy and confidence to support the uptake of a potential COVID-19 
vaccine, as well as to bolster overall immunization programs for all 
vaccine-preventable diseases.
Online content
Any methods, additional references, Nature Research report-
ing summaries, source data, extended data, supplementary infor-
mation, acknowledgements, peer review information; details of 
author contributions and competing interests; and statements of 
Table 2 | univariate regression outputs for vaccine acceptability questions against demographics and variables of interest
Beta-coefficients of vaccine questions (95% CIs) Beta-coefficients of business question (95% CIs)
Age (years) 25–54 vs 18–24, 1.12 (1.01, 1.25) 25–54 vs 18–24, 0.95 (0.86, 1.05)
55–64 vs 18–24, 1.21 (1.04, 1.40) 55–64 vs 18–24, 0.84 (0.73, 0.96)
65+ vs 18–24, 1.73 (1.48, 2.02) 65+ vs 18–24, 0.78 (0.68, 0.89)
Sex Male vs female, 0.84 (0.78, 0.91) Male vs female, 0.87 (0.81, 0.93)
Other vs female, 0.22 (0.14, 0.33) Other vs female, 0.32 (0.21, 0.49)
Income $2–$8 vs <$2, 1.38 (1.09, 1.74) $2–8 vs <$2, 0.91 (0.72, 1.14)
$8–$32 vs <$2, 1.87 (1.53, 2.29) $8–32 vs <$2, 1.04 (0.85, 1.27)
$32+ vs <$2, 2.18 (1.79, 2.64) $32+ vs <$2, 1.47 (1.21, 1.79)
Refused vs <$2, 0.91 (0.71, 1.16) Refused vs <$2, 0.78 (0.61, 1.00)
Education Medium vs low, 1.26 (1.15, 1.39) Medium vs low, 1.26 (1.15, 1.37)
High vs low, 1.34 (1.21, 1.48) High vs low, 1.24 (1.13, 1.36)
Very high vs low, 1.45 (1.25, 1.69) Very high vs low, 1.31 (1.15, 1.49)
Myself or family sick with COVID-19 Yes vs no, 0.97 (0.87, 1.08) Yes vs no, 1.05 (0.96, 1.71)
Cases per million population Middle vs low, 1.60 (1.46, 1.75) Middle vs low, 1.30 (1.20, 1.42)
High vs low, 1.55 (1.42, 1.71) High vs low, 1.62 (1.49, 1.76)
Mortality per million population Middle vs low, 1.38 (1.25, 1.52) Middle vs low, 1.25 (1.15, 1.37)
High vs low, 1.43 (1.30, 1.56) High vs low, 1.28 (1.18, 1.39)
Trust in government Yes vs no, 1.67 (1.54, 1.80) Yes vs no, 2.34 (2.20, 2.56)
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data and code availability are available at https://doi.org/10.1038/
s41591-020-1124-9.
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Methods
We analyzed two questions from the COVID-SCORE study pertaining to  
COVID-19 vaccine acceptance21. In that survey, participants responded to a total  
of 22 items, including two related to vaccine uptake, one related to trust in 
pandemic information sources and standard demographic questions regarding  
age, gender, level of education and household income (Supplementary Table 1).
Study participants. Participants were recruited by Consensus Strategies through 
multiple international online panel providers for each country to avoid coverage 
bias: Dynata provided 7,423 respondents across all 19 countries; Opinion Access 
provided 3,293 respondents from 14 countries; Survey Monkey provided 1,941 
responses from 12 countries; and Amazon MTurk provided 762 respondents 
from eight countries. Respondents’ identities were verified using IP addresses 
and mobile phone numbers to ensure that each participant was real and unique 
upon initial registration. Participants were recruited for the panels via a variety of 
methods, including online, telephone and direct mail solicitation. Sampling was 
random and is described in detail elsewhere21.
This study was approved by Emerson College, USA (institutional review board 
protocol no. 20–023-F-E-6/12), with an expiration date of June 11, 2021. The 
online questionnaire was administered by Emerson College to gather information 
from respondents after obtaining their written, informed consent about the survey 
and this project. No personally identifiable information was collected or stored.
Data collection. Survey data were collected from June 16 to June 20, 2020, from 
an online panel of 13,426 respondents aged 18 years or older from 19 countries 
from among the top 35 countries affected by the pandemic in terms of cases per 
million population, ranging between 619 and 773 participants per country. To 
ensure regional representation, we selected the next most affected country from 
regions not represented on the top 35 list: Brazil, Canada, China, Ecuador, France, 
Germany, India, Italy, Mexico, Nigeria, Poland, Russia, Singapore, South Africa, 
South Korea, Spain, Sweden, the United Kingdom and the United States22.
The more general vaccine-related question was, ‘If a COVID-19 vaccine is 
proven safe and effective and is available to me, I will take it’. Respondents were 
also asked to register their level of agreement with a second statement: ‘I would 
follow my employer’s recommendation to get a COVID-19 vaccine once the 
government has approved it as safe and effective’. Responses were recorded on 
a five-point Likert scale (‘completely disagree’, ‘somewhat disagree’, ‘neutral/no 
opinion’, ‘somewhat agree’ and ‘completely agree’). We examined the demographic 
breakdown of the responses to these questions. Data for age and income were 
collected through open-text fields. Age was coded into age categories: 18–24, 
25–54, 55–64 and 65 years or older. Where respondents provided income 
information, the levels were categorized as ‘<(US)$2 per day’, ‘$2–$8 per day’, 
‘$8–$32 per day’ and ‘$32+ per day’. Education levels were categorized as less than 
high school (low), high school or some college (medium), bachelor’s degree (high) 
and postgraduate degree (very high). Gender was defined as male, female or other. 
We also collected information on whether the respondent or a family member had 
been sick with COVID-19 and COVID-19 cases and deaths per million population 
at the country level22. For cases per million population and mortality per million 
population, we categorized the continuous values into categories of low, medium 
and high. For cases per million population, low was defined as fewer than 2,000 
cases per million population; medium was defined as between 2,000 and 4,000 
cases per million population; and high was defined as more than 4,000 cases per 
million population. For mortality per million population, low was defined as fewer 
than 200 deaths per million population; medium was defined as between 200 and 
400 deaths per million population; and high was defined as more than 400 deaths 
per million population.
Analysis. We analyzed the distribution of the responses against the different 
questions for the entire dataset and further examined differences by country. We 
calculated results for two sets of univariate regressions: one for each of the two 
questions related to vaccines. We used logistic regression, defining the outcome 
as 1 if a respondent answered ‘completely agree’ or ‘somewhat agree’ and 0 for any 
other response. The independent demographic variables included age, gender, 
income and education. We also examined the relationship between the two 
regression outcomes and whether someone in the respondent’s family had been 
sick with COVID-19, as well as existing country-by-country data on COVID-19 
cases per million population, COVID-19 mortality per million population and 
whether a respondent reported that they trusted pandemic information from their 
government (yes or no).
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
All data used in this analysis can be found at https://osf.io/kzq69/.
Code availability
All code to reproduce this analysis can be found at https://osf.io/kzq69/.
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Extended Data Fig. 1 | ‘If a COVID-19 vaccine is proven safe and effective and is available, I will take it’. Numbers above the bars represent the percent of 
respondents in each country who responded positively to the question ‘If a COVID-19 vaccine is proven safe and effective and is available, I will take it’.
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